Prostate Cancer Therapeutics Market Will Witness Growth Based On Adoption Of Innovative Technologies In Screening & Diagnostic Tests Till 2025:Grand View Research,inc.
The global prostate cancer therapeutics market is
expected to reach USD 12.0 billion by 2025, according to a new report by Grand
View Research, Inc. According to the American Cancer Society, approximately 1
in 7 men will be diagnosed with prostate cancer in their lifetime. As per
Cancer Research, a government institute, in the UK, 46,690 new cases of
prostate cancer were diagnosed out of which 11,287 patients died in 2014.
Supportive initiatives undertaken
by key players in collaboration with various governments to create more
awareness of clinical symptoms about prostate cancer and availability of
screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and
Digital Rectal Exam (DRE) resulting in early detection. Early detection helps
in quick and on time treatment and assists in deciding treatment regimens. In
addition, major players including Astella, Inc., Sanofi, Dendreon Corporation,
AstraZeneca, and Johnson & Johnson are focusing on development of effective
and safe therapeutic products to treat tumor. Moreover, these players have
various established brands such as Zytiga, Xtandi, Eligard, Taxotere, Provenge,
and Xofigo, which hold a strong position in the market. In addition, there are
many drugs in pipeline such as Tc-99m (Progenics), radium-223 dichloride
(Xofigo, Bayer), and ODM-201 (Orion and Bayer), which are in their phase 3
studies and are expected to enter the market during the forecast period. In
addition, patents of many existing products are expiring during the forecast
period. As a result, generic products are anticipated to penetrate the market.
All these factors together are expected to propel growth.
In Canada, Prostate Cancer
Foundation of Canada supports research, cure, and prevention of prostate cancer
through an online portal. This portal provides detailed information regarding
symptoms, diagnosis, and commercially available treatment options. Such portals
offer free access to people all around the world, which is resulting in growth.
Browse full research report on Prostate Cancer
Therapeutics Market: http://www.grandviewresearch.com/industry-analysis/prostate-cancer-therapeutics-market
Further key findings from the study suggest:
- The growing incidence of prostate cancer across the
globe is expected to drive growth
- The market is segmented into hormonal therapy
including Luteinizing Hormone Releasing Hormone (LHRH) agonist, LHRH
antagonist & antiandrogen; chemotherapy; immunotherapy, and targeted
therapy
- Zytiga (Johnson & Johnson) is considered as a
gold standard product for the treatment of prostate cancer and holds a
strong position. However, Xtandi (Astella, Inc.) and Zytiga are competing
with each other. The degree of competition is projected to elevate during
the forecast period. Thus, hormonal therapy holds the largest share.
- Provenge (Dendreon Corporation) is the only
immunotherapy drug mainly used in the treatment of advanced or metastasis
of such cancerous cells
- In addition, there are many promising immunotherapy
drugs in the pipeline such as INO-5150 SynCon and PROSTVAC (Bavarian
Nordic), which are expected to enter the market in the near future. Thus,
this drug class is projected to be the fastest growing segment.
- North America dominated the global market. Rising
prevalence and mortality rate associated with such tumors in the U.S. is
the primary reason for the dominance of the region.
- Asia Pacific is anticipated to be the fastest growing
region over the forecast period. Rising awareness regarding prostate
cancer in Asian countries including China, Japan, & India, would be
the major factor driving the growth.
- Some of the major players include, but are not
limited to, Johnson & Johnson; Astella, Inc.; Sanofi; Ipsen; Bayer AG;
AstraZeneca; Valeant Pharmaceuticals North America LLC (Dendreon
Corporation). These major players dominate the market owing to their
strong brand identity and extensive geographic reach.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the prostate cancer
therapeutics market by drug and region:
Drugs Outlook (Revenue, USD billion; 2014 - 2025)
- Hormonal
Therapy
- Luteinizing
Hormone-Releasing ormone (LHRH) Antagonists
- Zytiga
- Gonax
- Luteinizing
Hormone-Releasing Hormone (LHRH) Agonists
- Lupron
- Zoladex
- Eligard
- Decapeptyl
- Vantas
- Others
- Anti-Androgen
- Xtandi
- Casodex
- Chemotherapy
- Taxotere
- Jevtana
- Immunotherapy
- Provenge
- Targeted
Therapy
- Xofigo
Regional Outlook (Revenue, USD billion; 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- China
- Japan
- Latin
America
- Mexico
- Brazil
- MEA
- South
Africa
Access Press Release
By Grand View Research: http://www.grandviewresearch.com/press-release/global-prostate-cancer-therapeutics-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
Comments
Post a Comment